To ask the Secretary of State for Health, when he expects NICE to announce its decision on approving the Vimizim form of elosulfase alfa.
15 September 2015
The National Institute for Health and Care Excellence (NICE) published further draft guidance on 2 September 2015 which recommends elosulphase alfa (Vimizim) for the treatment of mucopolysaccharidosis (type IVA)/Morquio syndrome, subject to certain conditions. Interested parties now have until 23 September to comment on NICE’s draft recommendation.
NICE now expects to publish its final guidance in January 2016.